![](/images/2013/post-sep.jpg)
Myocardial Ischemia Market Size, Share, Revenue, Trends And Drivers For 2024-2033
The Business Research Company's Myocardial Ischemia Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
LONDON, GREATER LONDON, UK, August 19, 2024 /EINPresswire.com/ -- The global myocardial ischemia market has experienced significant growth in recent years. It is projected to increase from $0.74 billion in 2023 to $0.79 billion in 2024, achieving a compound annual growth rate (CAGR) of 6.7%. Despite challenges from various factors, the market is anticipated to reach $1.04 billion by 2028 at a compound annual growth rate (CAGR) of 7.0%, driven by rising prevalence of heart-related diseases and advancements in treatment options.
Rising Incidence of Diabetes Drives Market Growth
One of the primary factors fueling the growth of the myocardial ischemia market is the increasing incidence of diabetes. Diabetes, characterized by the body’s inability to produce or effectively use insulin, significantly raises the risk of myocardial ischemia. The prevalence of diabetes is escalating due to factors such as obesity, lack of physical activity, and genetic predispositions. According to the International Diabetes Federation (IDF), the number of adults aged 20–79 living with diabetes globally was approximately 537 million in 2021. This figure is expected to rise to 643 million by 2030 and 783 million by 2045. The growing prevalence of diabetes is anticipated to boost demand for myocardial ischemia diagnostic and therapeutic solutions.
Explore comprehensive insights into the global myocardial ischemia market with a detailed sample report:
https://www.thebusinessresearchcompany.com/sample_request?id=16488&type=smp
Key Players and Innovations
Major players in the myocardial ischemia market include Cardinal Health Inc., Pfizer Inc., Roche Holding AG, Bayer AG, and Sanofi SA, among others. These companies are at the forefront of developing innovative treatments to manage myocardial ischemia. For example, Agepha Pharma launched Lodoco (colchicine) in June 2023, an FDA-approved treatment targeting cardiovascular inflammation. This drug aims to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death. Lodoco’s approval highlights the industry's commitment to advancing treatment options for myocardial ischemia.
Trends Shaping the Market
Several trends are influencing the myocardial ischemia market:
• Adoption of Treatments: Increased adoption of myocardial ischemia treatments and advancements in healthcare infrastructure.
• Digital Health Solutions: Integration of digital health solutions and launches of cardiac rehabilitation programs.
• Innovations in Treatment: Continuous advancements in treatment options, driven by both pharmaceutical innovations and technological enhancements.
Market Segmentation
The myocardial ischemia market is segmented as follows:
• By Type: Symptomatic, Asymptomatic
• By Treatment and Diagnosis: Diagnosis, Treatment
• By End-User: Hospitals and Clinics, Diagnostic Centers, Ambulatory Surgery Centers
Regional Insights: North America Leading the Market
North America led the myocardial ischemia market in 2023, thanks to advanced healthcare infrastructure and high awareness levels. However, Europe is expected to be the fastest-growing region in the forecast period, driven by increasing healthcare expenditure and growing patient awareness.
Explore the report store to make a direct purchase of the report
https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report
Myocardial Ischemia Global Market Report 2024 from TBRC covers the following information:
• Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Trends, opportunities, strategies and so much more.
The Myocardial Ischemia Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on myocardial ischemia market size, myocardial ischemia market drivers and trends, myocardial ischemia market major players, competitors' revenues, market positioning, and market growth across geographies. The myocardial ischemia market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.
Browse Through More Similar Reports By The Business Research Company:
Myocardial Infarction Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/myocardial-infarction-global-market-report
Critical Limb Ischemia Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/critical-limb-ischemia-global-market-report
Cardiac Pacemakers Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cardiac-pacemakers-global-market-report
About The Business Research Company?
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.
Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Oliver Guirdham
The Business Research Company
+ +44 20 7193 0708
email us here
Visit us on social media:
Facebook
X
LinkedIn
YouTube
![](https://companies.einnews.com/tracking/article.gif?aid=736031070§ion=einpresswire&a=rUxmTUUMdB-9aUxE&i=sxNRWwLPJ__yn7ez)
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.